Tower Research Capital (TRC)’s CAS Medical Systems, Inc. CASM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-2,380
Closed -$6K 4721
2019
Q1
$6K Sell
2,380
-7,480
-76% -$16.1K ﹤0.01% 3025
2018
Q4
$16K Buy
9,860
+9,479
+2,488% +$17.7K ﹤0.01% 2147
2018
Q3
$1K Sell
381
-4,985
-93% -$10.6K ﹤0.01% 3685
2018
Q2
$10K Buy
+5,366
New +$8K ﹤0.01% 2815
2016
Q3
Sell
-339
Closed -$1K 4944
2016
Q2
$1K Buy
339
+82
+32% +$154 ﹤0.01% 4296
2016
Q1
$0 Buy
257
+84
+49% +$137 ﹤0.01% 5363
2015
Q4
$0 Buy
173
+71
+70% +$100 ﹤0.01% 5390
2015
Q3
$0 Sell
102
-716
-88% -$847 ﹤0.01% 5173
2015
Q2
$1K Buy
818
+620
+313% +$805 ﹤0.01% 4158
2015
Q1
$0 Sell
198
-1,914
-91% -$2.76K ﹤0.01% 5201
2014
Q4
$3K Buy
+2,112
New +$3.73K ﹤0.01% 3210
2014
Q3
Sell
-100
Closed 5134
2014
Q2
$0 Sell
100
-200
-67% -$424 ﹤0.01% 4923
2014
Q1
$1K Sell
300
-4,937
-94% -$10.5K ﹤0.01% 4274
2013
Q4
$9K Buy
+5,237
New +$8.17K ﹤0.01% 3125
2013
Q3
Sell
-2,512
Closed -$4K 5009
2013
Q2
$4K Buy
+2,512
New +$4.65K ﹤0.01% 3156

Tower Research Capital (TRC)'s CASM Position: Q2 2019 in Review

Tower Research Capital (TRC) sold out of CAS Medical Systems, Inc. (CASM) in Q2 2019, closing a stake of 2,380 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in CASM in Q2 2013 and held it in 15 quarters. The position peaked at $16K in Q4 2018. 0 funds tracked by Wall St. Rank hold CASM as of Q2 2019.

  • Tower Research Capital (TRC) reported no remaining CAS Medical Systems, Inc. position as of Q2 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,380 CAS Medical Systems, Inc. shares in Q2 2019, an estimated $6K.
  • Tower Research Capital (TRC) first reported a position in CAS Medical Systems, Inc. in Q2 2013 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s CAS Medical Systems, Inc. position peaked at $16K in Q4 2018.
  • 0 funds tracked by Wall St. Rank held CAS Medical Systems, Inc. as of Q2 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2019, filed 13 Aug 2019.